BRAF and cancer: Multiple lines of evidence including mutual exclusivity of RAS- and BRAF-mutations in many cancers highlight the RAF-MEK-ERK kinase cascade (ERK-MAPK pathway) as a key effector of RAS oncogenic properties and multiple small molecule inhibitors of this pathway have been developed4.